Literature DB >> 6133307

Dopamine, serotonin and alpha-adrenergic receptor blocking activities in serum and their relationships to prolactin level in schizophrenic patients receiving long-term chlorpromazine treatment.

T Nakahara, M Hirano, H Uchimura, M Saito, J S Kim, T Matsumoto, H Yokoo, M Shimomura, A Mukai.   

Abstract

The clinical application of a dopamine radioreceptor assay for neuroleptics has been proposed. Simultaneous monitoring of serum antidopaminergic (anti-DA), antiserotonergic (anti-5HT) antiadrenergic (anti-NA) activities may provide a better understanding of clinical effects of neuroleptics. Serum anti-DA and anti-5HT activities were estimated by competition for 3H-spiperone binding to dopamine and serotonin receptors in rat brain, respectively, and anti-NA activity by competition for 3H-WB-4101 binding to alpha-receptors. Thirty-one patients receiving maintenance doses of chlorpromazine (CPZ) chronically were studied. Serum activities varied among patients receiving the same dose, but correlated significantly with dose. Anti-DA activity also correlated with both anti-5HT anti-NA activities, and the average ratio of anti-5HT or anti-NA to anti-DA activity was slightly reduced by metabolism of CPZ. However, some patients had a different spectrum of serum activities from that of in vitro activities. Serum prolactin (PRL) correlated weakly with all the serum activities. The serum PRL anti-DA activity ratio appeared to be independent of anti-5HT or anti-NA activity, suggesting the predominant involvement of anti-DA activity in the stimulation of PRL release.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6133307     DOI: 10.1007/bf00427825

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  21 in total

1.  Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain.

Authors:  S J Peroutka; D C U'Prichard; D A Greenberg; S H Snyder
Journal:  Neuropharmacology       Date:  1977-09       Impact factor: 5.250

2.  A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood.

Authors:  I Creese; S H Snyder
Journal:  Nature       Date:  1977-11-10       Impact factor: 49.962

3.  Clinical significance of plasma chlorpromazine levels. II. Plasma levels of the drug, some of its metabolites and prolactin in patients receiving long-term phenothiazine treatment.

Authors:  T Kolakowska; D H Wiles; M G Gelder; A S McNeilly
Journal:  Psychopharmacology (Berl)       Date:  1976-08-26       Impact factor: 4.530

4.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

5.  Effects of serotonin precursors and melatonin on serum prolactin release in rats.

Authors:  K H Lu; J Meites
Journal:  Endocrinology       Date:  1973-07       Impact factor: 4.736

6.  The possible role of metabolites in therapeutic response to chlorpromazine treatment.

Authors:  G Sakalis; T L Chan; S Gershon; S Park
Journal:  Psychopharmacologia       Date:  1973-09-28

7.  Neuroleptic blood levels and therapeutic effect.

Authors:  B M Cohen; J F Lipinski; H G Pope; P Q Harris; R I Altesman
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

8.  Interaction of oxypertine with rat brain monoamine receptors.

Authors:  T Nakahara; M Kojima; H Uchimura; M Hirano; J S Kim; T Matsumoto
Journal:  Biochem Pharmacol       Date:  1980-10-01       Impact factor: 5.858

9.  The effect of neuroleptics on serum prolactin in schizophrenic patients.

Authors:  H Y Meltzer; V S Fang
Journal:  Arch Gen Psychiatry       Date:  1976-03

10.  Clinical significance of plasma drug and prolactin levels during acute chlorpromazine treatment: a replication study.

Authors:  T Kolakowska; M Orr; M Gelder; M Heggie; D Wiles; M Franklin
Journal:  Br J Psychiatry       Date:  1979-10       Impact factor: 9.319

View more
  1 in total

1.  Anticholinergic activity in the serum of patients receiving maintenance disopyramide therapy.

Authors:  E Iisalo; L Aaltonen
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.